Cardiovascular Inflammation Reduction Trial

Status: open

Cardiovascular Inflammation Reduction Trial (CIRT): A randomized, double-blind, placebo-controlled, event-driven trial of weekly low-dose methotrexate (LDM) in the prevention of cardiovascular events among stable coronary artery disease patients.

Treatment for Coronary Artery Disease

Contact Us Or call 251-471-7027

Description

The Cardiovascular Inflammation Reduction Trial (CIRT) is a randomized clinical trial investigating whether taking low-dose methotrexate reduces heart attacks, strokes, or death in people with type 2 diabetes or metabolic syndrome that have had a heart attack or multiple coronary blockages. This trial is funded by the National Heart, Lung, and Blood Institute (NHLBI)/National Institutes of Health (NIH). This trial is held at the Moorer Building which is located on the University Hospital's campus.

Sponsors

This trial is sponsored by National Heart Lung and Blood Institute.

Providers Associated With This Trial

Sub Investigators

This link will open in a new tab or window.